BREAKING NEWS:
VOIANT ACQUIRES VOXELERON
VIOANT, a leader in clinical trial imaging solutions, is thrilled to announce the acquisition of Voxeleron, a pioneering company in AI-driven ophthalmic image analysis. This strategic acquisition marks a significant advancement in Voiant’s mission to accelerate the development of innovative treatments for eye diseases.
AI-powered analysis and insights for breakthrough ophthalmic therapies.
to help you evaluate trial endpoints
with real-time access to data and insights
for an unmatched customer experience
“Over the past decade the Voxeleron team has assisted with numerous advanced image analyses, computer vision evaluations, and cross-platform standardization. Recently, iNebula has provided a functional, easy, and simple interface for us to share image data from 103 study patients with various stakeholders in our development plan. A system like this is invaluable when managing large image datasets.”
“In partnering with Voxeleron, we are using the most intuitive and accurate common-platform OCT analysis methods available, which provides advantages that are directly passed along to our trial sponsors.”
Watch: How Allgenesis Uses Imaging, Biomarkers and Post-hoc Analysis in its Phase 2 DME Trial
